Objective: Rare copy number variants (CNVs)-deletions and duplications-have recently been established as important risk factors for both generalized and focal epilepsies. A systematic assessment of the role of CNVs in epileptic encephalopathies, the most devastating and often etiologically obscure group of epilepsies, has not been performed. Methods: We evaluated 315 patients with epileptic encephalopathies characterized by epilepsy and progressive cognitive impairment for rare CNVs using a high-density, exon-focused, whole-genome oligonucleotide array. Results: We found that 25 of 315 (7.9%) of our patients carried rare CNVs that may contribute to their phenotype, with at least one-half being clearly or likely pathogenic. We identified 2 patients with overlapping deletions at 7q21 and 2 patients with identical duplications of 16p11.2. In our cohort, large deletions were enriched in affected individuals compared to controls, and 4 patients harbored 2 rare CNVs. We screened 2 novel candidate genes found within the rare CNVs in our cohort but found no mutations in our patients with epileptic encephalopathies. We highlight several additional novel candidate genes located in CNV regions. Interpretation: Our data highlight the significance of rare CNVs in the epileptic encephalopathies, and we suggest that CNV analysis should be considered in the genetic evaluation of these patients. Our findings also highlight novel candidate genes for further study. ANN NEUROL 2011;70:974-985 E pilepsy is often associated with major comorbidities, most frequently cognitive difficulties, which can be static or progressive. In the former, a variety of disorders are believed to cause both static intellectual disability and View this article online at wileyonlinelibrary.com.
epilepsy; in the latter, the epileptic process contributes to cognitive impairment. Epileptic encephalopathies (EEs), recently defined as severe epilepsies in which the epileptic activity, in addition to the seizures, contributes to cognitive impairment or regression, account for a significant proportion of the refractory epilepsies usually associated with poor outcome. 1 Most of the EEs begin in infancy or childhood, often in the setting of normal development with subsequent cognitive decline. In this way, the EEs differ considerably from disorders with static intellectual disability. Copy number variants (CNVs) have been established as an important source of mutation in many neurocognitive and neuropsychiatric conditions, including intellectual disability (ID), autism spectrum disorders, and schizophrenia. 2 CNVs are regarded as causative in >10% of cases of ID. 3 More recently, both targeted [4] [5] [6] and genome-wide 7, 8 discovery of CNVs in individuals with epilepsy have also established the importance of CNVs in the epilepsies. We previously evaluated >500 individuals with various types of pharmacoresponsive epilepsy for rare, potentially pathogenic CNVs, which were present in nearly 10% of patients. 7 The majority of patients in that series had genetic (idiopathic) generalized or focal epilepsies. However, a small number had more severe forms of epilepsy, and a greater percentage of these patients carried rare, potentially pathogenic CNVs. Although there have been reports of CNVs in some cases, 9-11 the EEs have not been systematically interrogated for CNVs as a group. In this study, we hypothesized that some EEs could be caused by CNVs and that genes within those CNVs would be novel candidate genes for EEs. We selected a cohort of 315 patients with EEs. We performed highdensity, whole-genome array comparative genomic hybridization (CGH) to determine what proportion of severe epilepsies may be caused by rare CNVs and to identify novel candidate genes within those regions.
Patients and Methods

Patient Samples
Patients with EEs for whom no cause was known were ascertained by referral and from the investigators' clinical practices. Detailed epilepsy, developmental, and general medical history was obtained with electroencephalography (EEG) and neuroimaging results. A seizure questionnaire was completed with the parents or caregivers where possible. 12 Strenuous efforts were made to obtain all previous medical records. Data were analyzed to determine each patient's phenotype and epilepsy syndrome according to the International League Against Epilepsy (ILAE) classifications. 1, [13] [14] [15] Patients who did not have a phenotype consistent with a well known epilepsy syndrome, but who did have an encephalopathic EEG with high-voltage diffuse background slowing and frequent epileptiform activity, and developmental slowing or regression, were classified according to the epileptiform pattern. For example, those with generalized spike and slow wave or sharp and slow wave activity were called symptomatic generalized epilepsies (SGEs) and those with unifocal or multifocal epileptiform abnormalities were classified as focal epilepsies with regression. This study was carried out with approval from the Human Research Ethics Committees of Austin Health and the Royal Children's Hospital (Victoria, Australia) and the human subjects review board at the University of Washington (Seattle, WA). All subjects or, in the case of minors or individuals with intellectual disability, parents or legal guardians gave informed consent to participate.
Array CGH and Analysis
We performed oligonucleotide array CGH using commercially available whole-genome, exon-focused arrays with 720,000 isothermal probes (Human CGH 3x720K Whole-Genome ExonFocused Array, Roche NimbleGen, Madison, WI). Probes were preferentially placed in exonic sequences but also distributed throughout nonexonic regions. Probe spacing was variable with a mean spacing of 4.2kb. Data were analyzed using Nimble Scan software followed by a 3-state hidden Markov model as previously described. 7 CNV calls were then filtered to eliminate: (1) events comprising <5 probes; (2) events that did not overlap any RefSeq genes; (3) events entirely within segmental duplications; and (4) events with >50% overlap with a CNV detected in 4,519 published controls, taking into account probe coverage and ability to detect a given CNV in those controls. 16, 17 For a subset of genomic regions that are prone to recurrent rearrangement and known to be associated with a range of neurocognitive disorders, we did not require absence of CNVs in controls, as it is well established that there is incomplete penetrance and a small number of controls carry CNVs in some of these regions (eg, 15q13, 16p11.2, 16p13, and 15q11.2; see Hotspot CNVs). All filtered events were also visually inspected in a genome browser. Candidate rare CNVs not seen in controls (all CNVs listed in Table 2 ) were validated using custom high-density arrays (Agilent Technologies, Santa Clara, CA). Parents were analyzed, where available, to determine if the CNV had arisen de novo or was inherited; parental phenotypes were taken into account to help to determine if the CNV was significant. We also considered CNV size and gene content when evaluating the likely pathogenicity of a CNV, following guidelines that have been published for the interpretation of clinical array CGH results in patients with ID, autism, or multiple anomalies. 3 Deletions involving known epilepsy genes (CDKL5, UBE3A, and CNTNAP2) were considered pathogenic. De novo deletions were considered pathogenic; de novo duplications were considered likely pathogenic; CNVs >1Mb that were inherited or of unknown inheritance were deemed likely pathogenic. In 2 cases, an inherited 500kb duplication of 16p11.2 was considered likely pathogenic because of the known disease associations with duplications at this locus as it may be contributing to the epilepsy phenotype. All other CNVs were considered of unknown significance due to size (<500kb), inheritance (inherited or unknown), or gene content (no known epilepsy genes).
Sequence Analysis
For each candidate gene (CACNA2D1 and LRRK2), targeted sequencing was performed for all exons, exon-intron boundaries, and 2kb upstream of the transcription start site using standard Sanger sequencing. Primer sequences are available upon request. CACNA2D1 was resequenced in 94 probands including 80 cases with epilepsy with myoclonic atonic seizures (MAE), 13 with Dravet syndrome, and 1 with genetic epilepsy with febrile seizures plus (GEFSþ) phenotype. Of these, 92 were from our cohort of 315 cases; 2 additional cases were selected for resequencing only. LRRK2 was resequenced in all 11 cases from our cohort with a diagnosis of migrating partial seizures of infancy (MPSI).
Results
We studied a cohort of 315 unrelated patients with epileptic encephalopathy (EE; Table 1 ). We identified 25 of 315 (7.9%) patients with 1 or more rare CNVs not seen in controls ( Table 2 ). The mean CNV size was 2.26Mb and median size was 510kb. Of these, 13 patients (4.1%) had CNVs that were clearly pathogenic (n ¼ 8) or likely pathogenic (n ¼ 5), and 12 had 1 or more rare CNVs that were not seen in controls but were of unclear clinical significance. Four individuals had 2 rare CNVs.
Inheritance
We evaluated 1 or both parents in all 25 cases to determine the inheritance pattern of all 29 rare CNVs (see Table 2 ). We identified 9 de novo, 8 maternally inherited, and 7 paternally inherited CNVs. In 1 case (T2761), the proband had a homozygous deletion and both parents were confirmed to be heterozygous carriers. In 3 cases (4 CNVs total) the CNVs were not present in the mother, but the father was unavailable for analysis.
Pathogenic CNVs
In 13 patients we considered the CNV(s) to be pathogenic or likely pathogenic based on size, gene content, de novo inheritance, or the previous literature (see Table 2 ). Clearly pathogenic CNVs include heterozygous deletions that disrupt a single, known gene in 2 cases: UBE3A in case T3334 and CDKL5 in case T2959. We also identified a homozygous deletion removing exon 2 of CNTNAP2 in case T2761 and his affected sibling. Ten other cases have CNVs encompassing multiple genes. Two probands have overlapping deletions of 7q21: T964 with a de novo 8Mb deletion of 7q11-q21 and T438 with a 4Mb deletion of 7q21 (Fig 1) . The 7q21 deletions have a 3Mb region of overlap that includes 6 genes: GNAI1, GNAT3, CD36, SEMA3C, HGF, and CAC-NA2D1. Other pathogenic CNVs include deletions of 10p13 (7257), 5q33-q34 (8893), and 4p16 (T1962) as well as 1 case with deletion of 9p24-p23 and adjacent duplication of 9p23-p21 (T3729). Likely pathogenic CNVs include a duplication of 16p11.2 in 2 cases ( Fig  2) and a deletion of 1q44 (T2363). In addition, we identified a likely pathogenic, novel, de novo 700kb duplication of 1q32 in case T3810 (Fig 3) . Additional rare CNVs of uncertain significance were present in 12 patients (see Table 2 , Fig 3) .
Hotspot CNVs
Certain regions of the genome are ''hotspots'' for recurrent CNVs due to the presence of large blocks of duplicated DNA that facilitate non-allelic homologous recombination at meiosis. 18 We identified 5 individuals with CNVs at hotspot regions. Two individuals (T16335 with West syndrome and T2547 with a multifocal epileptic encephalopathy) have duplications of proximal 16p11.2 (chr16:29.5-30.0Mb; see Fig 2) . We also identified rearrangements of uncertain significance at hotspot regions in case T18349 with SGE (distal 16p11.2 deletion), case T3467 with continuous spike and wave during slow sleep (CSWS; duplication of distal 22q11), and case 8245 with MAE (deletion of proximal 15q13.3, BP3-BP4) (see Table 2 ). We did not detect CNVs at distal 15q13.3 (BP4-BP5), 16p13.11, or 15q11.2, loci known to be important for GGE and some focal epilepsies. 4, 6, 8 Sequence Analysis of Candidate Genes We selected 2 candidate genes for sequence analysis: CACNA2D1 and LRRK2 (Table 3) . CACNA2D1, which is deleted in 2 patients (T438 with MAE and T964 with SGE), was resequenced in 94 probands. No convincing mutations were identified (see Table 3 ). LRRK2, deleted in patient T2709 with MPSI, was resequenced in 10 additional patients from our cohort with MPSI. In addition, the nondeleted allele was sequenced in the original proband. No deleterious changes were identified.
Discussion
We performed genome-wide exon-focused array CGH in a series of 315 patients with epileptic encephalopathies in order to identify novel genomic regions and candidate genes and to investigate how frequently CNVs were responsible for these phenotypes. Overall, we found that 7.9% of affected individuals carried at least 1 rare CNV. In 4.1%, we identified clearly pathogenic CNVs. These findings suggest that array CGH should be considered in the genetic evaluation of individuals with EE. Rare CNVs were most commonly identified in patients with focal epilepsy with regression, epilepsy-aphasia syndrome, and symptomatic generalized epilepsy (see Table 1 ) but were not identified in any of the patients with Lennox Gastaut syndrome or devastating epileptic encephalopathy in school-age children. Investigation of larger cohorts of specific EE should be carried out to further evaluate whether this apparent difference is significant. Within our cohort, we identified both de novo and inherited CNVs. While we considered those that are de novo most likely to be pathogenic, many of the rare inherited CNVs contain brain-expressed genes involved in synaptic transmission and axonal guidance and are likely to contribute to the patient's phenotype. Indeed, even for the recurrent deletions at 15q13.3 and 16p13.11, which are clearly associated with epilepsy risk, there are many examples of unaffected carrier parents, incomplete penetrance and variable expressivity. The same may be true for some of the rare inherited CNVs identified in this study, and in these cases there may be additional genetic or non-genetic factors that also play a role in the clinical presentation.
Pathogenic Events and Novel Candidate Genes
In several cases we found clearly pathogenic deletions that involved known epilepsy genes and had clear genotype-phenotype correlation, albeit atypical features in some instances. These include deletion of Xp22 resulting in the disruption of CDKL5 in a boy who had an EE with the typical picture of a 3-stage evolution of seizures characteristically seen in girls with CDKL5 encephalopathy 19 and also reported in rare male cases. 10 We also found an atypical deletion of 15q11 that disrupted UBE3A in a man with MAE who had features reminiscent of Angelman syndrome. Another man with MAE had a 6.5Mb deletion of 5q33-q34 encompassing a cluster of genes encoding subunits of the GABA-A receptor. Mutations in 2 of the genes in the deleted region, GABRA1 and GABRG2, have been associated with JME 20 and GEFSþ and CAE, 21, 22 respectively. We identified a homozygous deletion of exon 2 of the CNTNAP2 gene in a pair of siblings of which the proband had focal epilepsy with regression; they shared some features in common with the Amish families reported by Strauss and colleagues. 23 We also identified several CNVs that provide insight into potentially novel candidate genes for epilepsy. Two probands had overlapping deletions of 7q21. Deletions of 7q11-q21 distal to the Williams-Beuren syndrome locus have been associated with infantile spasms, with considerable interest in the gene MAGI2.
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YWHAG and HIP1 have also been proposed as candidate genes for the infantile spasm phenotype. 25 While patient T964 with SGE carried a large de novo deletion that included MAGI2, YWHAG, and HIP1, Patient T438 had a 4Mb deletion that did not include these genes. Furthermore, neither of our patients had spasms. Given the similarity in phenotypes of the 2 probands, we focused on the 6 genes that were deleted in both patients as candidates for sequencing. One of the genes in the region of overlap is CACNA2D1, which encodes the alpha-2/delta subunit of brain voltage-dependent calcium channels that bind the anti-epileptic drug, gabapentin. 26 Therefore, we considered CACNA2D1 an excellent candidate gene for MAE and related phenotypes. We performed sequence analysis in 94 probands with MAE or Dravet syndrome phenotypes but did not detect any clearly deleterious mutations. Interestingly, the smaller 4Mb deletion in the patient with MAE segregated with a range of epilepsy and cognitive phenotypes in the proband's family (see Fig 1) . The deletion was found in family members with markedly different phenotypic severity ranging from the EEs of MAE and Dravet syndrome to febrile seizures plus, consistent with the GEFSþ spectrum, and even GGE. 27 All affected family members had learning difficulties; affected children all had marked behavioral problems. Thus the 7q21 deletion may be acting as 1 of several genetic factors that contribute to the more severe phenotype of MAE and Dravet syndrome in the setting of complex inheritance rather than acting as a monogenic cause. We have not screened CACNA2D1 in other phenotypes, but given the presence of GGE in the proband's mother, a cohort of patients with GGE would be worth testing. Alternatively, another gene in the deleted region may be responsible for the phenotypes in this family. We identified a 510kb deletion in patient T3472 with Dravet syndrome that disrupts the ADAM23 gene (see Fig 3) . The deletion is not found in the mother's genome, but we were unable to evaluate the father. ADAM23 knockout mice have aberrant dendrite morphology and exhibit seizures in the neonatal period, and heterozygous mice are susceptible to PTZ-induced seizures. 28 Furthermore, ADAM23 is part of a complex that contains LGI1, ADAM22, and Kv1.1 29 and has been shown to directly bind LGI1, 28 mutations of which cause autosomal dominant partial epilepsy with auditory features in humans. 30, 31 It is possible that disruption of ADAM23 in our patient leads to Dravet syndrome. Case T3810 with an epilepsy-aphasia syndrome carries a de novo 700kb duplication of 1q32 that involves 13 genes (see Fig 3) . One of these is SYT2, a member of the synaptotagmin family of genes that encode membrane proteins expressed at the synapse that are thought to act as calcium sensors. 32, 33 It is possible that excess SYT2 disrupts normal synaptic transmission in our patient.
Hotspot CNVs
Recurrent deletions at three rearrangement ''hotspots''-15q13.3 (BP4-BP5), 16p13.11, and 15q11.2-have recently been identified as important risk factors for epilepsy. [4] [5] [6] 8 Each of these deletions is found in up to 1% of individuals with epilepsy, and each has also been associated with ID, autism, and/or schizophrenia. [34] [35] [36] [37] [38] [39] [40] [41] While heterozygous 15q13.3 deletions have been found almost exclusively in patients with GGE, deletions at the other loci have been found in patients with a broader range of epilepsies. We identified 1 patient with an inherited deletion BP3-BP4 on 15q13. This deletion is proximal to the BP4-BP5 deletion that has been associated with epilepsy, and the clinical significance is not clear. 42 Interestingly, we did not identify any CNVs at 15q13.3 (BP4-BP5), 16p13.11, or 15q11.2, suggesting that heterozygous deletions of these regions may be primarily associated with the more common and milder forms of epilepsy, although homozygous 15q13.3 deletions have been associated with a severe phenotype. 43 We did identify CNVs at several other hotspot regions that have been associated with neurocognitive disorders. Interestingly, 2 individuals in the EE cohort have duplications of proximal 16p11.2 (chr16: 29.5-30.0Mb), which we considered to be likely pathogenic. T16335 had West syndrome and autism spectrum disorder and T2547 had multifocal epileptic encephalopathy. Duplications of this region have been associated with ID, schizophrenia, and autism. [44] [45] [46] We previously reported one individual with JME and the same duplication, 7 and
Bedoyan and colleagues 47 reported a de novo duplication of this region in a child with EE that the authors felt was consistent with MPSI. We did not find this duplication in 11 cases with MPSI. We were able to evaluate relatives of case T16335 and found that the duplication was also present in the proband's sister who also had West syndrome, and father, both of whom had autism spectrum disorder. Similar to the deletions of 15q13.3, 15q11.2, and 16p13.11, duplications at 16p11.2 appear to be a risk factor for a wide range of neurocognitive and neuropsychiatric disorders, including different types of epilepsy, autism, ID, and schizophrenia, though the mechanism underlying such highly variable expression is not yet known. 48, 49 As discussed in the next section, we also identified a deletion of distal 16p11.2 in a patient with a second deletion. 56 We hypothesized that complete loss of function of LRRK2 might lead to the MPSI phenotype in our patient, but we were unable to detect a mutation in the nondeleted allele (see Table 3 ). Although each deletion in T2709 is inherited, the combination of both may contribute to the phenotype. Case T3729 has a 9Mb terminal deletion of chromosome 9p and an adjacent 18.5Mb duplication. The terminal deletion in our patient is similar to 1 described by Heinzen and colleagues 8 in a patient with unclassified epilepsy, developmental delay, dysmorphic features, and spastic quadriplegia. Finally, Patient T3467 with CSWS and her affected brother both have 2 duplications. One involves the distal part of the common 22q11 deletion syndrome region. The second duplication involves the 3 0 end of the DOK5 gene. However, both duplications are inherited from their unaffected mother, making it less likely that either is a highly penetrant pathogenic CNV.
Two Hits
Excess of Large Deletions
In our cohort, we find 12 CNVs that are >1Mb in 11 (3.5%) individuals (see Table 2 ). Of these, 7 (2.2%) have a large deletion, 3 (1.0%) have a large duplication, and 1 patient has 1 of each. In contrast, in a set of 2,493 control individuals, Itsara and colleagues 16 found that 1.6% of controls had a CNV > 1Mb; 0.3% had a large deletion, and 1.3% had a large duplication. Together, these reports confirm the importance of rare CNVs in the genetic etiology of the epilepsies and emphasize the need for the evaluation of larger series of patients to better understand the pathogenic significance, especially for rare inherited CNVs.
Conclusions
In summary, this is the first report of genome-wide CNV discovery in a large series of patients with EEs. We identified rare CNVs in 7.9% of 315 patients, at least onehalf of which are likely to be pathogenic and which largely differ from CNVs found in milder epilepsies. Our results also illuminate several novel candidate genes for epilepsy in humans that deserve further study, including CACNA2D1, SLC1A3, and ADAM23. Comprehensive sequence analysis of these and other candidate genes in extended cohorts will help determine whether point mutations contribute to the genetic etiology of each EE.
We suggest that array CGH should be considered in the genetic evaluation of this patient population, in whom the occurrence of severe epilepsy and regression often prompts extensive and frequently negative investigations. While the interpretation of array CGH results in the clinical setting can be complicated by results of unclear significance, the application of established guidelines can facilitate interpretation and counseling. 3 Furthermore, as this tool is applied more widely to epilepsy cohorts in both the clinic and the research laboratory, comparison of CNVs across studies will clarify which specific CNVs are clearly pathogenic and begin to illuminate novel genes, pathways and syndromes in the epileptic encephalopathies.
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